-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Chronic Myelomonocytic Leukemia (CMML) Drug Details: Nivolumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Repotrectinib in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Repotrectinib in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Repotrectinib in Melanoma Drug Details: Repotrectinib (Augtyro) acts as an anti-neoplastic agent....
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-576
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-576 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-819
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-819 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STAR-0602 in Vaginal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STAR-0602 in Vaginal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STAR-0602 in Vaginal Cancer Drug Details: STAR-0602 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-95775 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Non-Hodgkin Lymphoma Drug Details: CC-95775 (FT-1101) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-95775 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Diffuse Large B-Cell Lymphoma Drug Details: CC-95775...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-95775 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Solid Tumor Drug Details: CC-95775 (FT-1101) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-95775 in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Basal Cell Carcinoma (Basal Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PLX-038 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PLX-038 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PLX-038 in Ovarian Cancer Drug Details: PLX-038 is under development for...